目的观察针灸联合补肾健脾活血方对骨质疏松症患者骨代谢、骨密度(bone mineral density,BMD)及免疫功能的影响。方法将80例肾虚血瘀型骨质疏松症患者随机分为对照组和研究组,每组40例。对照组采取补肾健脾活血方治疗,研究组在对照组基...目的观察针灸联合补肾健脾活血方对骨质疏松症患者骨代谢、骨密度(bone mineral density,BMD)及免疫功能的影响。方法将80例肾虚血瘀型骨质疏松症患者随机分为对照组和研究组,每组40例。对照组采取补肾健脾活血方治疗,研究组在对照组基础上联合针灸治疗。观察两组治疗前后BMD、骨代谢参数、中医证候积分变化,并比较两组不良反应。结果治疗后,两组BMD均升高(P<0.05),骨碱性磷酸酶(bone alkaline phosphatase,BAP)、骨钙素(osteocalcin,OC)水平升高(P<0.05),Ⅰ型胶原交联氨基端肽(N-telopeptide of typeⅠcollagen,NTXI)水平下降(P<0.05),CD4^(+)T细胞、CD4^(+)/CD8^(+)水平均升高(P<0.05),CD8^(+)T细胞水平降低(P<0.05),中医证候积分均降低(P<0.05);且研究组上述指标均优于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论针灸联合补肾健脾活血方治疗骨质疏松症,可改善患者骨代谢、BMD和中医证候积分,增强免疫功能。展开更多
目的评价氯化锶(^(89)SrCl_2)联合局部放疗治疗骨转移瘤的疗效及不良反应。方法计算机检索Pub Med、Embase、Cochrane资料库、中文科技期刊全文数据库、中国生物医学文献数据库、万方数据库和中国期刊全文数据库,收集公开发表的关于^(89...目的评价氯化锶(^(89)SrCl_2)联合局部放疗治疗骨转移瘤的疗效及不良反应。方法计算机检索Pub Med、Embase、Cochrane资料库、中文科技期刊全文数据库、中国生物医学文献数据库、万方数据库和中国期刊全文数据库,收集公开发表的关于^(89)SrCl_2联合局部放疗的对照研究,对纳入的研究提取资料并进行质量评价,采用Rev Man 5.3软件进行统计分析。结果共纳入7个研究548例患者。^(89)SrCl_2联合局部放疗的骨痛缓解有效率高于单用^(89)SrCl_2治疗或局部放疗(P<0.05)。^(89)SrCl_2联合局部放疗的骨显像有效率与单用^(89)SrCl_2治疗或局部放疗治疗比较,差异无统计学意义(P>0.05)。^(89)SrCl_2联合局部放疗常见不良反应为骨髓抑制,主要表现为白细胞、血小板降低,对症治疗后可恢复。结论^(89)SrCl_2联合局部放疗治疗可提高恶性肿瘤骨转移患者的骨痛缓解有效率,其出现的不良反应与单用^(89)SrCl_2或局部放疗相似。展开更多
Gastroenteropancreatic neuroendocrine neoplasms(GEP-NENs)are a rare group of tumors originating from neuroendocrine cells of the digestive system.Their incidence has increased over the last decades.The specific pathog...Gastroenteropancreatic neuroendocrine neoplasms(GEP-NENs)are a rare group of tumors originating from neuroendocrine cells of the digestive system.Their incidence has increased over the last decades.The specific pathogenetic mechanisms underlying GEP-NEN development have not been completely revealed.Unfunctional GEP-NENs are usually asymptomatic;some grow slowly and thus impede early diagnosis,which ultimately results in a high rate of misdiagnosis.Therefore,many GEP-NEN patients present with later staged tumors.Motivated hereby,research attention for diagnosis and treatment for GEP-NENs increased in recent years.The result of which is great progress in clinical diagnosis and treatment.According to the most recent clinical guidelines,improved grading standards can accurately define poorly differentiated grade 3 neuroendocrine tumors and neuroendocrine carcinomas(NECs),which are subclassified into large and small cell NECs.Combining different functional imaging methods facilitates precise diagnosis.The expression of somatostatin receptors helps to predict prognosis.Genetic analyses of mutations affecting death domain associated protein(DAXX),multiple endocrine neoplasia type 1(MEN 1),alpha thalassemia/intellectual disability syndrome X-linked(ATRX),retinoblastoma transcriptional corepressor 1(RB 1),and mothers against decapentaplegic homolog 4(SMAD 4)help distinguishing grade 3 NENs from poorly differentiated NECs.The aim of this review is to summarize the latest research progress on diagnosis and treatment of GEP-NENs.展开更多
Objective A certain fraction of patients failed palliative treatment of 153Sm-ethylenediaminetetramethy lenephosphate ( 153Sm-EDTMP) for painful skeletal metastases were reviewd. A comparative analysis was des...Objective A certain fraction of patients failed palliative treatment of 153Sm-ethylenediaminetetramethy lenephosphate ( 153Sm-EDTMP) for painful skeletal metastases were reviewd. A comparative analysis was designed to identify the factors related to therapeutic response. Methods From a 3-year multi-center clinical trial, 51 cases were collected who did not respond to an intravenous injection of 153Sm-EDTMP at a dosage of 0.5-1.5 mCi/kg. The therapeutic efficacy was evaluated via changes of symptoms, general condition, consumption of analgesics, sum of effect product, and Karnofsky scores. The age, sex, history of treatment, tumor type, location of bony involvement, uptake ratio and number of metastases, and doses used by the patients were compared to those of the responders. Results In 51 non-responders, 43 were male, 34 suffered from lung cancer, 41 had bone lesions in the vertebrae, 39 in the pelvis, and 24 had metastases in the lower extremities. Sex distribution, tumor type and location of the lesion differed significantly between responders and non-responders. No other factor showed differences between the two groups. Though patients of younger age, and lesions with lower uptake of radiopharmaceutical seemed to fail the treatment more easily as observed clinically, this was not confirmed by statistical analysis. Conclusion The sex of the patients, certain types of primary tumors and metastases to lower parts of the body were found to influence the patients’ response to a single dose of 153Sm-EDTMP palliation. Further exploration of a better way to determine dosage and predict response for each individual case is needed.展开更多
文摘目的观察针灸联合补肾健脾活血方对骨质疏松症患者骨代谢、骨密度(bone mineral density,BMD)及免疫功能的影响。方法将80例肾虚血瘀型骨质疏松症患者随机分为对照组和研究组,每组40例。对照组采取补肾健脾活血方治疗,研究组在对照组基础上联合针灸治疗。观察两组治疗前后BMD、骨代谢参数、中医证候积分变化,并比较两组不良反应。结果治疗后,两组BMD均升高(P<0.05),骨碱性磷酸酶(bone alkaline phosphatase,BAP)、骨钙素(osteocalcin,OC)水平升高(P<0.05),Ⅰ型胶原交联氨基端肽(N-telopeptide of typeⅠcollagen,NTXI)水平下降(P<0.05),CD4^(+)T细胞、CD4^(+)/CD8^(+)水平均升高(P<0.05),CD8^(+)T细胞水平降低(P<0.05),中医证候积分均降低(P<0.05);且研究组上述指标均优于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论针灸联合补肾健脾活血方治疗骨质疏松症,可改善患者骨代谢、BMD和中医证候积分,增强免疫功能。
文摘目的评价氯化锶(^(89)SrCl_2)联合局部放疗治疗骨转移瘤的疗效及不良反应。方法计算机检索Pub Med、Embase、Cochrane资料库、中文科技期刊全文数据库、中国生物医学文献数据库、万方数据库和中国期刊全文数据库,收集公开发表的关于^(89)SrCl_2联合局部放疗的对照研究,对纳入的研究提取资料并进行质量评价,采用Rev Man 5.3软件进行统计分析。结果共纳入7个研究548例患者。^(89)SrCl_2联合局部放疗的骨痛缓解有效率高于单用^(89)SrCl_2治疗或局部放疗(P<0.05)。^(89)SrCl_2联合局部放疗的骨显像有效率与单用^(89)SrCl_2治疗或局部放疗治疗比较,差异无统计学意义(P>0.05)。^(89)SrCl_2联合局部放疗常见不良反应为骨髓抑制,主要表现为白细胞、血小板降低,对症治疗后可恢复。结论^(89)SrCl_2联合局部放疗治疗可提高恶性肿瘤骨转移患者的骨痛缓解有效率,其出现的不良反应与单用^(89)SrCl_2或局部放疗相似。
基金Supported by China Scholarship Council,No. 202108080085 to (Dai M) and No. 201908080127 to (Lu LL)
文摘Gastroenteropancreatic neuroendocrine neoplasms(GEP-NENs)are a rare group of tumors originating from neuroendocrine cells of the digestive system.Their incidence has increased over the last decades.The specific pathogenetic mechanisms underlying GEP-NEN development have not been completely revealed.Unfunctional GEP-NENs are usually asymptomatic;some grow slowly and thus impede early diagnosis,which ultimately results in a high rate of misdiagnosis.Therefore,many GEP-NEN patients present with later staged tumors.Motivated hereby,research attention for diagnosis and treatment for GEP-NENs increased in recent years.The result of which is great progress in clinical diagnosis and treatment.According to the most recent clinical guidelines,improved grading standards can accurately define poorly differentiated grade 3 neuroendocrine tumors and neuroendocrine carcinomas(NECs),which are subclassified into large and small cell NECs.Combining different functional imaging methods facilitates precise diagnosis.The expression of somatostatin receptors helps to predict prognosis.Genetic analyses of mutations affecting death domain associated protein(DAXX),multiple endocrine neoplasia type 1(MEN 1),alpha thalassemia/intellectual disability syndrome X-linked(ATRX),retinoblastoma transcriptional corepressor 1(RB 1),and mothers against decapentaplegic homolog 4(SMAD 4)help distinguishing grade 3 NENs from poorly differentiated NECs.The aim of this review is to summarize the latest research progress on diagnosis and treatment of GEP-NENs.
文摘Objective A certain fraction of patients failed palliative treatment of 153Sm-ethylenediaminetetramethy lenephosphate ( 153Sm-EDTMP) for painful skeletal metastases were reviewd. A comparative analysis was designed to identify the factors related to therapeutic response. Methods From a 3-year multi-center clinical trial, 51 cases were collected who did not respond to an intravenous injection of 153Sm-EDTMP at a dosage of 0.5-1.5 mCi/kg. The therapeutic efficacy was evaluated via changes of symptoms, general condition, consumption of analgesics, sum of effect product, and Karnofsky scores. The age, sex, history of treatment, tumor type, location of bony involvement, uptake ratio and number of metastases, and doses used by the patients were compared to those of the responders. Results In 51 non-responders, 43 were male, 34 suffered from lung cancer, 41 had bone lesions in the vertebrae, 39 in the pelvis, and 24 had metastases in the lower extremities. Sex distribution, tumor type and location of the lesion differed significantly between responders and non-responders. No other factor showed differences between the two groups. Though patients of younger age, and lesions with lower uptake of radiopharmaceutical seemed to fail the treatment more easily as observed clinically, this was not confirmed by statistical analysis. Conclusion The sex of the patients, certain types of primary tumors and metastases to lower parts of the body were found to influence the patients’ response to a single dose of 153Sm-EDTMP palliation. Further exploration of a better way to determine dosage and predict response for each individual case is needed.
